Source: BusinessWire
Parnell has acquired Noble Pharma LLC, strengthening its U.S. manufacturing capabilities and supporting long-term growth. The acquisition adds an FDA- and DEA-accredited facility in Wisconsin, enhancing Parnell’s ability to produce a wide range of pharmaceutical products, including liquids, tablets, gels, and creams. Company leadership said the move improves supply continuity, expands production capacity, and reinforces Parnell’s commitment to delivering high-quality products and reliable service to customers and partners. The integration of Noble Pharma’s established operations is expected to accelerate innovation and support the company’s growing product portfolio.
Overall, the acquisition positions Parnell for continued expansion in the U.S. market, enabling it to better meet demand while strengthening its operational footprint and competitive advantage in the Animal Health industry.